These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The aetiology and pathogenesis of multiple sclerosis. Adams CW; Hallpike JF Guys Hosp Rep; 1969; 118(2):263-86. PubMed ID: 4896181 [No Abstract] [Full Text] [Related]
6. Pathogenesis of myelin/oligodendrocyte damage in multiple sclerosis. Dhib-Jalbut S Neurology; 2007 May; 68(22 Suppl 3):S13-21; discussion S43-54. PubMed ID: 17548563 [TBL] [Abstract][Full Text] [Related]
7. [Prospects of an immunologic therapy of multiple sclerosis]. Fasanaro G; Gentile A; Stella L Acta Neurol (Napoli); 1972; 27(4):367-78. PubMed ID: 5085161 [No Abstract] [Full Text] [Related]
8. Pathology of multiple sclerosis. Seitelberger F Ann Clin Res; 1973 Oct; 5(5):337-44. PubMed ID: 4792208 [No Abstract] [Full Text] [Related]
9. [Interaction of central nervous system local immunity and systemic immunity during multiple sclerosis]. Tourtellotte WW Rev Neurol (Paris); 1972 Nov; 127(5):497-504. PubMed ID: 4588993 [No Abstract] [Full Text] [Related]
10. Molecular "negativity" may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. Musse AA; Harauz G Int Rev Neurobiol; 2007; 79():149-72. PubMed ID: 17531841 [TBL] [Abstract][Full Text] [Related]
12. Neuroimmunology of multiple sclerosis and experimental allergic encephalomyelitis. Stuerzebecher S; Martin R Neuroimaging Clin N Am; 2000 Nov; 10(4):649-68 ,vii-viii. PubMed ID: 11359717 [TBL] [Abstract][Full Text] [Related]
13. Skin reactions to myelin antigen and purified encephalitogenic factor in multiple sclerosis. Cendrowski W; Murawski K Arch Immunol Ther Exp (Warsz); 1966; 14(2):164-9. PubMed ID: 5914140 [No Abstract] [Full Text] [Related]
14. An in-vitro approach to the study of oligodendrocytes and their involvement in multiple sclerosis. Szuchet S; Dumas M Neurol Clin; 1983 Aug; 1(3):729-55. PubMed ID: 6680171 [TBL] [Abstract][Full Text] [Related]
15. [Will there soon be a sub-type specific treatment? New approaches to multiple sclerosis therapy]. MMW Fortschr Med; 2008 Apr; 150(15):17. PubMed ID: 18510111 [No Abstract] [Full Text] [Related]
17. The peculiarities of the antibrain antibodies in multiple sclerosis and other diseases accompanied by myelin destruction. Gannushkina IV; Sukhorukova LI; Zavalishin IA Acta Neurol (Napoli); 1985; 7(3-4):323-7. PubMed ID: 4061144 [No Abstract] [Full Text] [Related]